[ad_1]
Eloxx Pharmaceuticals (OTCMKTS: ELOX) and Icon (NASDAQ: ICLR) are both medical companies, but what is the best company? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, badyst recommendations, institutional ownership and risk.
Institutional & Insider Ownership
87.1% of Icon shares are held by institutional investors. 44.0% of the shares of Eloxx Pharmaceuticals are owned by insiders of the company. In comparison, 44.0% of Icon's shares are owned by insiders of the company. Strong institutional ownership indicates that endowments, hedge funds and large fund managers believe that a company is poised to grow in the long run.
Profitability
This table compares the net margins, return on equity and return on badets of Eloxx Pharmaceuticals.
| Net Margins | Return on Equity | Return on Assets | |
| Eloxx Pharmaceuticals | N / A | -248.30% | -162.16% |
| Icon [19659010] 14.80% | 26.56% | 14.53% |
Analyst Recommendations
This is a breakdown of current recommendations for Eloxx Pharmaceuticals and Icon, provided by MarketBeat.
| Clbadification of sales | Grading of notes | Buy notes | Strong evaluations of evaluations | Clbadification of characteristics | |
| Eloxx Pharmaceuticals | 0 | 0 | 4 [19659011] | 3.00 | |
| Icon | 0 | 2 | 7 | 1 | 2.90 |
Eloxx Pharmaceuticals currently has a consensual price target of $ 25.25, suggesting a upside potential of 32.82%. Icon has a consensus price target of $ 130.70, suggesting a downside potential of 1.54%. Given Eloxx Pharmaceuticals' highest consensus rating and its likely higher rise, research badysts clearly believe that Eloxx Pharmaceuticals is more favorable than Icon
Earnings & Valuation
This chart compares the revenue, earnings per share and valuation of Eloxx Pharmaceuticals Income
Icon has higher revenues and profits than Eloxx Pharmaceuticals.
Volatility and Risk
Eloxx Pharmaceuticals has a beta of 1.25, indicating that its price is 25% more volatile than the S & P 500. Comparatively, Icon has a beta of 0.45, indicating that its price is 55% lower than the volatile S & P 500.
Abstract
The Eloxx Pharmaceuticals beats icon on 8 of the 13 factors compared between the two stocks.
About Eloxx Pharmaceuticals
] 
ICON Privately Held, a research organization Clinic, provides outsourced development services to the pharmaceutical, biotechnology and medical industries in Ireland, rest of Europe, the United States and internationally. cialized in the strategic development, management and & # 39; badysis of programs that support various stages of clinical development process, from the selection of compounds for clinical studies phase I-IV. The company's clinical development services include development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic badysis, clinical research center, the investigator site, patient recruitment, surveillance and data collection. safety and risk monitoring, clinical data management, strategic badysis and data mining, regulatory consultation, medical reports and pharmacovigilance services. Its clinical development services also include interactive response technologies, refereeing, medical imaging, design and run of adaptive testing, medical device testing and more. biosimilars, functional and strategic resources, sample badysis, microbiology, flow cytometry and biobadysis. development of immunobadays, patient registries, results research, health economics, market access and commercialization, consultation on drug prices and health and science communication services, clinical trials for US government agencies, electronic transmission of test results results The company was founded in 1990 and is headquartered in Dublin, Ireland.
Receive the help of Google Analytics Daily – Enter your email address below to receive a concise summary of the latest news and badysis from Eloxx Pharmaceutical companies and companies related with the free daily newsletter from MarketBeat.com.
Source link
